ValueSets and Code Systems (active)
This is the list of ValueSets and CodeSystems defined for use within the UK Core.
Other ValueSets are useable if the binding strength is defined as extensible. For more information see HL7 FHIR - Binding Strengths.
The UK Core ValueSets have been assigned a maturity level similar to the maturity levels described in the FHIR standard. This is intended to indicate how stable the ValueSet is deemed to be, this is in addition to the publication status of the ValueSet HL7 FHIR statuses of draft, active, retired and unknown.
| Maturity level | Definition |
|---|---|
| 0 | The ValueSet has been published on the current build. This ValueSet has had no formal review and therefore may have quality issues. It is published only to allow the review process to start |
| 1 | The ValueSet produces no warnings during the build process and has had a formal internal review by the UK Core development team |
| 2 | The ValueSet has been released for review to the UK FHIR community, any feedback received has been addressed as far as possible |
| 3 | The ValueSet has been presented for inclusion in the Technical and Clinical Assurance process |
| 4 | The ValueSet has completed the Technical and Clinical Assurance process and the status has been changed to active |
| 5 | The ValueSet has been presented for inclusion in the HL7 UK Ballot Process |
| 6 | The ValueSet has completed the HL7 UK Ballot process and is now deemed to be Normative |
For the current list of ValueSets or CodeSysytems under development refer to the HL7 FHIR® UK Core Profile Implementation Guide R4 (Draft) ValueSets and Code Systems.
Where more than one CodeSystem is listed the associated ValueSet should be expanded to give the full list of codes
In the interim, the content logical definitions for these ValueSets simply include a reference to a URL for the whole of dm+d, whilst the descriptions textually provide the constraints on the applicable dm+d concept classes that are relevant to the ValueSet.
The ValueSets affected by this issue are:
If you need further information about this please contact the Interoperable Medicines Standards programme via the Contact Us page.